Reimbursement and Market Access for Pharmaceuticals in Taiwan
Obtain a high drug reimbursement price from the National Health Insurance Administration.
To learn more about Taiwan drug reimbursement, please contact us.
Taiwan, like many advanced healthcare systems, balances the benefits and costs of drugs. The organization that does this is called the National Health Insurance Administration (NHIA). Drugs in Taiwan are classified as new drugs (Class 1 and 2), new items with identical dosage forms, and APIs that are already included in the National Health Insurance List and biosimilars. Reimbursement classes determine separate reimbursement paths. New drugs that are classified as Class I are priced at the average of the 10 reference advanced countries, while new drugs in Class 2 are generally priced at the cheapest price in the same reference countries. The NHIA also has reimbursement formulas for generics and biosimilars as well as other formulas.
To apply for drug reimbursement on Taiwan’s National Health Insurance, applicants should look at the NHIA website and then the – Pharmaceutical Benefit and Reimbursement Scheme (PBRS). Also, sometimes applicants will want to follow up after submitting their reimbursement application with a consultation session with the Health Technology Assessment Division.
To learn more about Taiwan drug reimbursement, please contact us.
Related Resources
Visit our Resource Center to view free webcasts and charts or read publications, news, and research reports on the Asia medical markets.
Related News Briefs
Visit our Resource Center to view free webcasts and charts or read publications, news, and research reports on the Asia medical markets.